{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T08:05:39Z","timestamp":1773216339210,"version":"3.50.1"},"reference-count":80,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Ustekinumab is a monoclonal antibody approved for the treatment of IBD. This drug has a well-established efficacy; however, patients may not respond or lose response. The availability of other biological therapies prompts the need for comparative data between different agents to suggest first- or second-line strategies. Aim of this review is to compare the effectiveness of ustekinumab to other biologics in Crohn\u2019s disease and ulcerative colitis, as well as report the available data on dose escalation and reinduction. A systematic electronic search of the English literature was performed up to November 2023, using Medline (PubMed), Web of Science, Scopus and the Cochrane Library. Conference proceedings were also screened. Out of 659 citations, 80 relevant articles were selected and included in the present narrative review. Head-to-head comparisons of different biological drugs are relatively scarce, mostly deriving from indirect comparison or retrospective studies. Overall available data indicate similar effectiveness in the treatment of IBD patients. Dose escalation and reinduction strategies are well documented, but the optimal treatment schedule is still to be defined. Response and remission rates vary in different studies, and a proportion of patients fail to achieve clinical and endoscopic outcomes. However, both approaches are effective and safe in nonresponders and secondary loss of response. IBD patients may benefit from dose escalation or reinduction. Both strategies prove effective in regaining response in a proportion of patients, avoiding unnecessary early switch. Head-to-head trials are still needed to determine the exact placement of this drug compared to other biologics.<\/jats:p>","DOI":"10.3390\/jcm13143993","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T07:16:07Z","timestamp":1720509367000},"page":"3993","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IBD Patients with Primary or Secondary Nonresponse to Ustekinumab Benefit from Dose Escalation or Reinduction"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1350-4876","authenticated-orcid":false,"given":"Filippo","family":"Vernia","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Monaco","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-5711","authenticated-orcid":false,"given":"Giovanni","family":"Latella","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Department of Life, Health and Environmental Sciences, University of L\u2019Aquila, 67100 L\u2019Aquila, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wang, S., and Li, J. (2021). Treatment of Inflammatory Bowel Disease: A Comprehensive Review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.765474"},{"key":"ref_2","first-page":"CD000544","article-title":"Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis","volume":"8","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_3","first-page":"CD008870","article-title":"Aminosalicylates for induction of remission or response in Crohn\u2019s disease","volume":"7","author":"Lim","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_4","first-page":"CD006884","article-title":"Methotrexate for maintenance of remission in Crohn\u2019s disease","volume":"2014","author":"Patel","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/ajg.2011.64","article-title":"Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"106","author":"Khan","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.gastro.2013.10.052","article-title":"Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis","volume":"146","author":"Panaccione","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_7","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease","volume":"10","author":"Chande","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/ajg.2016.524","article-title":"Improvements in the Long-Term Outcome of Crohn\u2019s Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSL Cohort","volume":"112","author":"Jeuring","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_9","first-page":"453","article-title":"Novel Therapies for Patients with Inflammatory Bowel Disease","volume":"18","author":"Santiago","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.gastro.2011.03.050","article-title":"Outcomes of patients with Crohn\u2019s disease improved from 1988 to 2008 and were associated with increased specialist care","volume":"141","author":"Nguyen","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","article-title":"The Burden of Inflammatory Bowel Disease in Europe in 2020","volume":"15","author":"Zhao","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.dld.2015.12.014","article-title":"Short term colectomy rate and mortality for severe ulcerative colitis in the last 40 years. Has something changed?","volume":"48","author":"Clemente","year":"2016","journal-title":"Dig. Liver Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40265-017-0765-6","article-title":"Ustekinumab: A Review in Moderate to Severe Crohn\u2019s Disease","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab Induction and Maintenance Therapy in Refractory Crohn\u2019s Disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"67","author":"Honap","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ueg2.12094","article-title":"The impact of ustekinumab on extraintestinal manifestations of Crohn\u2019s Disease: A post hoc analysis of the UNITI studies","volume":"9","author":"Narula","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/03007995.2023.2178148","article-title":"Treatment persistence among bio-na\u00efve patients with Crohn\u2019s disease initiated on ustekinumab or Adalimumab","volume":"39","author":"Zhdanava","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Seo, G.H., and Jung, S.H. (2023). Comparison of the Persistence of Anti-TNF Agents and Ustekinumab in Patients with Crohn\u2019s Disease: A Study Based on the Korean National Database. J. Clin. Med., 12.","DOI":"10.3390\/jcm12062397"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.14740\/gr1194","article-title":"Comparative Effectiveness of Ustekinumab Versus Adalimumab in Induction of Clinical Response and Remission in Crohn\u2019s Disease: Experience of a Real-World Cohort at a Tertiary Care Inflammatory Bowel Disease Referral Center","volume":"12","author":"Ahmed","year":"2019","journal-title":"Gastroenterol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1007\/s10620-023-07897-2","article-title":"Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn\u2019s Disease","volume":"68","author":"Eriksson","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Albshesh, A., Bannon, L., Sharar Fischler, T., Truyens, M., Vavricka, S.R., Tepes, K., Pugliese, D., Savarino, E.V., Zittan, E., and Drobne, D. (2023). Comparison of Short- and Long-Term Effectiveness between Anti-TNF and Ustekinumab after Vedolizumab Failure as First-Line Therapy in Crohn\u2019s Disease: A Multi-Center Retrospective Cohort Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072503"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.14309\/ajg.0000000000001773","article-title":"An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn\u2019s Disease Patients\u2019 Failure to TNF-Alpha Inhibitors","volume":"117","author":"Onali","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/apt.15706","article-title":"The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor","volume":"51","author":"Alric","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Rayer, C., Nachury, M., Bourreille, A., Roblin, X., Peyrin-Biroulet, L., Viennot, S., Flamant, M., Laharie, D., Caron, B., and Dewitte, M. (2022). Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a frst anti-TNF agent in patients with Crohn\u2019s disease: A multicentre retrospective study. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02583-5"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hyun, H.K., Zhang, H.S., Yu, J., Kang, E.A., Park, J., Park, S.J., Park, J.J., Kim, T.I., Kim, W.H., and Cheon, J.H. (2022). Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn\u2019s disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02225-w"},{"key":"ref_29","first-page":"25","article-title":"Efficacy and Safety of Guselkumab for Crohn\u2019s Disease Through 3 Years: Galaxi-1 Long-Term Extension","volume":"11","author":"Afzali","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_30","first-page":"77","article-title":"Efficacy of Guselkumab in Patients with Moderately to Severely Active Crohn\u2019s Disease not in Clinical Response at Week 12: Results from The Galaxi 1 Study","volume":"11","author":"Panaccione","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_31","first-page":"919","article-title":"Risankizumab versus Ustekinumab for Patients with Moderate to Severe Crohn\u2019s Disease: Results from the Phase 3b Sequence Study","volume":"11","author":"Chapman","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/ueg2.12068","article-title":"Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn\u2019s disease","volume":"9","author":"Buisson","year":"2021","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00384-018-3212-6","article-title":"Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: A matched case analysis","volume":"34","author":"Novello","year":"2019","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_34","first-page":"68","article-title":"Comparative Effectiveness of Ustekinumab and Adalimumab in the Prevention of Post-Operative Recurrence in Crohn\u2019s Disease","volume":"11","author":"Allez","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ecco-jcc\/jjz119","article-title":"Ustekinumab for Crohn\u2019s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study","volume":"14","author":"Biemans","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.cgh.2020.02.035","article-title":"Effectiveness of Ustekinumab Dose Escalation in Patients with Crohn\u2019s Disease","volume":"19","author":"Ollech","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1756284820959245","DOI":"10.1177\/1756284820959245","article-title":"Ustekinumab dose escalation improves clinical responses in refractory Crohn\u2019s disease","volume":"13","author":"Haider","year":"2020","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/ibd\/izaa282","article-title":"Predictors of Ustekinumab Failure in Crohn\u2019s Disease After Dose Intensification","volume":"27","author":"Dalal","year":"2021","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"Effectiveness and safety of ustekinumab intensification at 90mg every four weeks In Crohn\u2019s disease: A multicenter study","volume":"15","author":"Fumery","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1097\/MEG.0000000000002275","article-title":"Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn\u2019s disease","volume":"33","author":"Kurent","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.14309\/01.ajg.0000592160.21664.18","article-title":"Ustekinumab Dose Escalation Is Effective in Treatment of Crohn\u2019s Disease","volume":"114","author":"Cohen","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1093\/ibd\/zaa010.189","article-title":"Ustekinumab dose escalation effective in real-world use for luminal and perianal Crohn\u2019s disease","volume":"26","author":"Glass","year":"2020","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1093\/ibd\/izac164","article-title":"Long-Term Outcomes After Ustekinumab Dose Intensification for Inflammatory Bowel Diseases","volume":"29","author":"Dalal","year":"2023","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"i564","DOI":"10.1093\/ecco-jcc\/jjac190.0566","article-title":"Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn\u2019s disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial","volume":"17","author":"Schreiber","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/apt.15784","article-title":"Effectiveness of ustekinumab dose escalation in Crohn\u2019s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy","volume":"52","author":"Kopylov","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/ibd\/izab015","article-title":"Re-induction with Intravenous Ustekinumab in Patients with Crohn\u2019s Disease and a Loss of Response to This Therapy","volume":"28","author":"Bermejo","year":"2022","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"i416","DOI":"10.1093\/ecco-jcc\/jjab232.560","article-title":"Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc","volume":"16","author":"Barrio","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.cgh.2020.07.064","article-title":"Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn\u2019s Disease Patients Already on Every-4-Week Dosing","volume":"19","author":"Sedano","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jcag\/gwac017","article-title":"Efficacy of Intravenous Ustekinumab Reinduction in Patients with Crohn\u2019s Disease with a Loss of Response","volume":"5","author":"Heron","year":"2022","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"i609","DOI":"10.1093\/ecco-jcc\/jjac190.0610","article-title":"Ustekinumab Dose Intensification Is Effective in One-Third of Asian Inflammatory Bowel Disease Patients, Results from A Tertiary Inflammatory Bowel Disease Centre","volume":"17","author":"Lim","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1016\/j.cgh.2021.10.002","article-title":"Effectiveness of re-induction and\/or dose escalation of ustekinumab in Crohn\u2019s disease: A systematic review and meta-analysis","volume":"20","author":"Meserve","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_52","first-page":"171","article-title":"Analysis of Baseline Characteristics Associated with Clinical Response to Ustekinumab IV Re-Induction Strategy in Patients with Crohn\u2019s Disease in The Power Trial","volume":"11","author":"Schreiber","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_53","first-page":"645","article-title":"Efficacy of Ustekinumab intensification and re-induction in Crohn\u2019s disease patients with insufficient or loss of response","volume":"7","author":"Truyens","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Su\u00e1rez Ferrer, C., Arroyo Arg\u00fcelles, J., Rueda Garc\u00eda, J.L., Garc\u00eda Ram\u00edrez, L., Martin Arranz, E., S\u00e1nchez Azofra, M., Poza Cord\u00f3n, J., Noci Belda, J., and Martin-Arranz, M.D. (2024). Intensification with Intravenous Ustekinumab in Refractory Crohn\u2019s Disease. J. Clin. Med., 13.","DOI":"10.3390\/jcm13030669"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/00365521.2021.1906315","article-title":"A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn\u2019s disease patients in Finland","volume":"56","author":"Sipponen","year":"2021","journal-title":"Scand J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"s956","DOI":"10.1016\/S0016-5085(20)33068-7","article-title":"Efficacy of dose intensification of ustekinumab in Crohn\u2019s disease","volume":"158","author":"Ramaswamy","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1080\/00365521.2022.2095668","article-title":"Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: A GETAID multicentre cohort study","volume":"57","author":"Meyer","year":"2022","journal-title":"Scand J. Gastroenterol."},{"key":"ref_59","first-page":"232","article-title":"Real-World Comparison of Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-Tnf Agent","volume":"11","author":"Fumery","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"i872","DOI":"10.1093\/ecco-jcc\/jjac190.0872","article-title":"Real-world evidence comparison on the effectiveness of ustekinumab vs anti-TNF or vedolizumab in ulcerative colitis: Induction phase results from the prospective, observational RUN-UC study","volume":"17","author":"Bokemeyer","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"i707","DOI":"10.1093\/ecco-jcc\/jjac190.0709","article-title":"Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: Results from the TORUS study","volume":"20","author":"Buisson","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_62","first-page":"174","article-title":"Real-World Comparison of Effectiveness between Tofacitinib and Ustekinumab in Patients with Ulcerative Colitis Exposed to at least One Anti-Tnf Agent: Long-Term Results from the Torus Study","volume":"11","author":"Buisson","year":"2023","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ibd\/izab097","article-title":"Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients with Ulcerative Colitis: A Propensity Score Analysis","volume":"27","author":"Dalal","year":"2021","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"i672","DOI":"10.1093\/ecco-jcc\/jjac190.0676","article-title":"Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison","volume":"20","author":"Reinisch","year":"2023","journal-title":"J. Crohns Colitis"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S403","DOI":"10.1093\/ecco-jcc\/jjz203.577","article-title":"Dose adjustment in patients with moderate-to-severe ulcerative colitis: Results from the UNIFI maintenance study long-term extension","volume":"14","author":"Danese","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.cgh.2021.03.028","article-title":"Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study","volume":"20","author":"Dalal","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"i383","DOI":"10.1093\/ecco-jcc\/jjab232.510","article-title":"Ustekinumab as an opportunity for refractory Ulcerative Colitis patients","volume":"16","author":"Iborra","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1093\/ibd\/izz291","article-title":"Two Cases of Inflammatory Bowel Disease Patients Treated with Ustekinumab 90 mg Every 3 Weeks","volume":"26","author":"Chatand","year":"2020","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients with Crohn\u2019s Disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.dld.2020.10.018","article-title":"Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus","volume":"53","author":"Amiot","year":"2021","journal-title":"Dig. Liver. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/ibd\/izac103","article-title":"Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn\u2019s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"29","author":"Shehab","year":"2023","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and Second-Line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative colitis: Medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/apt.16802","article-title":"Systematic review with meta-analysis: Loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases","volume":"55","author":"Yang","year":"2022","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn\u2019s disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S331","DOI":"10.1093\/ecco-jcc\/jjz203.475","article-title":"Single-centre experience of ustekinumab: Therapeutic drug monitoring in Crohn\u2019s disease patients","volume":"14","author":"Liefferinckx","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00535-017-1324-3","article-title":"Systematic review with meta-analysis: Loss of response and requirement of anti-TNF\u03b1 dose intensification in Crohn\u2019s disease","volume":"52","author":"Qiu","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2018.06.026","article-title":"Loss of response to vedolizumab and ability of dose intensification to restore response in patients with Crohn\u2019s disease or ulcerative colitis: A systematic review and meta-analysis","volume":"17","author":"Danese","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"107074","DOI":"10.1016\/j.phrs.2024.107074","article-title":"Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project","volume":"200","author":"Ingrasciotta","year":"2024","journal-title":"Pharmacol. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohns Colitis"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/3993\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:11:57Z","timestamp":1760109117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/14\/3993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,9]]},"references-count":80,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13143993"],"URL":"https:\/\/doi.org\/10.3390\/jcm13143993","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,9]]}}}